Intuitive Surgical (NASDAQ:ISRG) Lowered to Hold Rating by Wall Street Zen

Key Points

• Intuitive Surgical has been downgraded from a "buy" to a "hold" rating by Wall Street Zen, reflecting analysts' cautious outlook on the stock.
• Despite the downgrade, other analysts such as Piper Sandler and Wells Fargo retain an "overweight" rating with increased price targets, indicating a differing perspective within the market.
• The company's stock recently traded at $441.12, with a market cap of $158.13 billion and a notable earnings performance reporting $2.19 EPS, surpassing analysts' expectations.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) was downgraded by research analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report released on Friday.

Other analysts have also recently issued research reports about the stock. Piper Sandler reiterated an "overweight" rating and issued a $595.00 price objective (up previously from $575.00) on shares of Intuitive Surgical in a research note on Wednesday, July 23rd. UBS Group lifted their price objective on shares of Intuitive Surgical from $547.00 to $585.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft reiterated a "sell" rating on shares of Intuitive Surgical in a research note on Friday, August 22nd. Wells Fargo & Company lifted their price objective on shares of Intuitive Surgical from $559.00 to $599.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 23rd. Finally, BTIG Research lifted their price objective on shares of Intuitive Surgical from $566.00 to $571.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Thirteen research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $595.95.

Intuitive Surgical Stock Performance

Shares of ISRG stock traded up $3.00 during midday trading on Friday, hitting $441.12. 1,940,488 shares of the company were exchanged, compared to its average volume of 2,508,160. The firm has a market capitalization of $158.13 billion, a P/E ratio of 61.52, a PEG ratio of 4.59 and a beta of 1.61. The firm's 50 day moving average price is $469.43 and its two-hundred day moving average price is $501.46. Intuitive Surgical has a 52 week low of $425.00 and a 52 week high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last issued its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 earnings per share for the quarter, topping the consensus estimate of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The business had revenue of $2.44 billion during the quarter, compared to analysts' expectations of $2.35 billion. During the same quarter in the previous year, the company earned $1.78 EPS. The business's revenue was up 21.4% on a year-over-year basis. Analysts expect that Intuitive Surgical will post 6.43 EPS for the current year.

Insider Activity

In related news, EVP Myriam Curet sold 4,500 shares of the company's stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $492.48, for a total transaction of $2,216,160.00. Following the completion of the transaction, the executive vice president directly owned 353 shares in the company, valued at $173,845.44. This represents a 92.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Amy L. Ladd sold 336 shares of the company's stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $470.11, for a total transaction of $157,956.96. Following the transaction, the director owned 1,074 shares of the company's stock, valued at approximately $504,898.14. This represents a 23.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,224 shares of company stock worth $21,716,492. 0.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently added to or reduced their stakes in the stock. Aaron Wealth Advisors LLC grew its holdings in Intuitive Surgical by 0.8% during the 2nd quarter. Aaron Wealth Advisors LLC now owns 2,528 shares of the medical equipment provider's stock worth $1,374,000 after acquiring an additional 19 shares during the last quarter. Crown Wealth Group LLC grew its holdings in Intuitive Surgical by 4.8% during the 1st quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after acquiring an additional 20 shares during the last quarter. FSM Wealth Advisors LLC grew its holdings in Intuitive Surgical by 3.8% during the 1st quarter. FSM Wealth Advisors LLC now owns 546 shares of the medical equipment provider's stock worth $270,000 after acquiring an additional 20 shares during the last quarter. CFO4Life Group LLC grew its holdings in Intuitive Surgical by 4.8% during the 1st quarter. CFO4Life Group LLC now owns 436 shares of the medical equipment provider's stock worth $216,000 after acquiring an additional 20 shares during the last quarter. Finally, J. W. Coons Advisors LLC grew its holdings in Intuitive Surgical by 1.4% during the 1st quarter. J. W. Coons Advisors LLC now owns 1,497 shares of the medical equipment provider's stock worth $741,000 after acquiring an additional 20 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.